whitepaper

Application note: A kinase inhibitor phenotypic screen using a multiplex T Cell activation assay

Posted: 22 June 2020 | | No comments yet

Modulating the TCR signaling pathway using biologics, small molecules or genetic engineering is highly relevant to many therapeutic areas including cancer immunotherapy, adoptive cell therapy, vaccine development and autoimmune disease.

Kinase inhibitor drugs specifically targeting early signaling events during T cell activation are a new focus for the treatment of autoimmune diseases. The development of these drugs and therapies regulating TCR activity require assays that can rapidly profile T cell function and health.

This application note describes high throughput screening of a library of kinase inhibitors for T-cell activation inhibition using primary human PBMCs by simultaneous evaluation of activation markers, cell proliferation and cytokines in a single assay.











    To read this application note in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


    *

    *

    *

    *

    *


    *

    *

    *

    *

    Are you interested in purchasing an advanced high throughput flow cytometry platform?

    Yes, in 0-3 monthsYes, in 3-6 monthsYes, in 6-12 monthsYes, in more than 12 monthsNo intent to purchase

     

    This content is provided to you for free thanks to the kind support of our sponsor: IntelliCyt Corporation

    Send this to a friend